newsfilter
← Earnings
Earnings Releases·

CorMedix Therapeutics — Third Quarter 2026 Earnings Summary

  • Reaffirmed full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in cash and cash equivalents as of September 30, 2026.
  • The 2027 ESRD PPS final rule establishes a Q1 2027 DefenCath post-TDAPA Add-on of $8.32 per session, which falls within the previously guided range of 3x to 5x the current $2.37 rate.
  • Management anticipates the average 2027 Add-on rate will exceed 2x the current $2.37 level, with projected quarterly fluctuations subject to CMS utilization data and calculation methodology.
  • Cautioned that third-party projections regarding 2027 quarterly adjustments are not company guidance and carry significant uncertainty due to the lack of visibility into future utilization and pricing data.
  • Scheduled a conference call for November 12, 2026, to discuss complete quarterly financial performance and additional business updates.
Company
CORMEDIX INC
Sector
Healthcare
Industry
Biotechnology